Kurtuluş Şahin - Concepedia

Author

Kurtuluş Şahin

University Hospital Carl Gustav Carus ORCID

Also Known As

K Sahin, K Şahin, K. Sahin, Kadir Kasım Sahin, Katharina Daschkow, Kurtulus Sahin, Kurtuluş Şahin

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University Hospital Carl Gustav Carus University of Cologne University of Rostock Heinrich Heine University Düsseldorf King's College London

KŞ

About

Kurtuluş Şahin is an author at University Hospital Carl Gustav Carus specializing in medicine, cardiovascular disease, and patient safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	381
2	Public Health	3	3	82
3	Pathology	3	3	133
4	Cell Biology	1	1	62
5	Emergency Medicine	1	1	12

Kurtuluş Şahin

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Jan Beyer‐Westendorf, Kati Förster, Sven Pannach, Blood	2014	399
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial Jan Beyer‐Westendorf, Sebastian Schellong, H. Gerlach, The Lancet Haematology ThrombosisVenous ThrombosisThromboembolic ComplicationsCardiovascular DiseaseSuperficial-vein Thrombosis	2017	166
Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation Judith S. Hecker, Sandra Marten, L Keller, Thrombosis and Haemostasis	2016	158
Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry J. Beyer-Westendorf, K. Förster, F. Ebertz, EP Europace	2015	141
Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in Neuroblastoma Holger Christiansen, Kurtuluş Şahin, Frank Berthold, European Journal of Cancer PathologyNeuroblastsMycn AmplificationDna AneuploidyChromosome 1	1995	62
The current contribution of molecular factors to risk estimation in neuroblastoma patients Frank Berthold, Kurtuluş Şahin, Barbara Hero, European Journal of Cancer Tumor BiologyNeuro-oncologyNeuroblastoma PatientsMedicineCurrent Contribution	1997	59
Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry Sindy Helmert, Sandra Marten, Heike Mizera, Journal of Thrombosis and Thrombolysis ThrombosisCardiovascular DiseaseDresden Noac RegistryMedicinePatient Safety	2017	35
Enhanced mobilization of the bone marrow–derived circulating progenitor cells by intracoronary freshly isolated bone marrow cells transplantation in patients with acute myocardial infarction Ramazan Gökmen Turan, I. Bozdag‐T, Çetin Turan, Journal of Cellular and Molecular Medicine	2011	34
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a<i>post hoc</i>analysis of the X-VeRT trial Stefan H. Hohnloser, Riccardo Cappato, Michael D. Ezekowitz, EP Europace	2015	28
Improved Functional Activity of Bone Marrow Derived Circulating Progenitor Cells After Intra Coronary Freshly Isolated Bone Marrow Cells Transplantation in Patients with Ischemic Heart Disease R. Goekmen Turan, I. Bozdag‐T, Jasmin Ortak, Stem Cell Reviews and Reports	2010	26

Page 1